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Background: The current study reports rates of knowledge regarding the probability of a BRCA1 and/or BRCA2 pathogenic variant 
and genetic testing in patients with breast cancer, collected as part of a randomized controlled trial of a tailored, comprehensive, and 
interactive decision tool (iCanDecide). Methods: A total of 537 patients newly diagnosed with early-stage breast cancer were en-
rolled at the time of their first visit in 22 surgical practices, and were surveyed 5 weeks (496 patients; Response Rate [RR], 92%) after 
enrollment after treatment decision making. Primary outcomes included knowledge regarding the probability of carrying a BRCA1 
and/or BRCA2 pathogenic variant and genetic testing after diagnosis. Results: Overall knowledge regarding the probability of hav-
ing a BRCA1 and/or BRCA2 pathogenic variant was low (29.8%). Significantly more patients in the intervention group compared with 
the control group had knowledge regarding the probability of a BRCA1 and/or BRCA2 pathogenic variant (35.8% vs 24.4%; P <.006). 
In multivariable logistic regression, the intervention arm remained significantly associated with knowledge regarding the probability 
of having a BRCA1 and/or BRCA2 pathogenic variant (odds ratio, 1.79; 95% confidence interval, 1.18-2.70). Conclusions: The results 
of the current study suggest that although knowledge concerning the probability of having a BRCA1 and/or BRCA2 pathogenic vari-
ant remains low in this patient population, the interactive decision tool improved rates compared with a static Web site. As interest 
in genetic testing continues to rise, so will the need to integrate tools into the treatment decision process to improve informed deci-
sion making. Cancer 2018;124:4000-4009 © 2018 American Cancer Society
KEYWORDS: BRCA1 and/or BRCA2, breast cancer patients, decision making, decision tool, diagnosis, genetic testing, knowledge, 
probability information.
INTRODUCTION
Advances in genetic technology, particularly multigene panel testing, have increased the clinical diagnostic and thera-
peutic uses of genetic testing in patients with breast cancer. However, results from multigene panel testing add to already 
difficult decisions regarding next steps in clinical care soon after a breast cancer diagnosis. The addition of multigene 
panel testing to the decision-making process requires additional knowledge, consideration, and the application of genetic 
risk information for the various treatment options. Given the association between genetic testing outcomes and treat-
ment use, knowledge is critical. Nevertheless, patient knowledge regarding breast cancer genetics and the implications 
of genetic test results for different treatment options is low,1,2 further widening the gap between the availability of more 
expansive genetic testing and the usefulness of the results from genetic testing in treatment decision making.3‒6
To the best of our knowledge, few tools have been developed for breast cancer–related decision making that address 
important aspects of genetic testing on the implications of test results for the treatment of individuals already diagnosed.7 
This is particularly concerning given that a previous study found that the most commonly reported immediate postdiag-
nosis concerns are treatment and prognosis, followed by the probability of developing a second cancer and the probability 
of family members developing cancer.8 Knowledge regarding the probability of carrying a BRCA1 and/or BRCA2 patho-
genic variant, as well as the uses and benefits of genetic testing, in individuals with a family history of breast and ovarian 
cancer have been well described.9,10 However, to our knowledge, only 3 tools have been designed specifically for women 
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with a pathogenic variant, or those already diagnosed 
with breast cancer.11‒13 Furthermore, we also believe that 
knowledge regarding the probability of BRCA1 and/or 
BRCA2 pathogenic variants and concerning the benefits 
and purpose of genetic testing in relation to treatment 
has not yet been assessed in patients with breast cancer 
after diagnosis. Few studies have formally evaluated the 
role of genetic testing in breast cancer treatment decision 
tools after a diagnosis of breast cancer. Because to our 
knowledge there is no consensus regarding what should 
be covered across the various phases of the genetic testing 
process (eg, health-related decision making, dissemination 
of results to family members), many tools lack important 
themes relevant to different points in the process.11,14,15
The purpose of the current analysis, which was con-
ducted after the successful completion of a large random-
ized controlled trial assessing the effect of a decision tool 
(iCanDecide) on decision making for the treatment of 
locoregional breast cancer, was 2-fold. First, we sought 
to determine whether patients with breast cancer who 
viewed the intervention version of iCanDecide would 
have higher rates of knowledge regarding BRCA1 and/
or BRCA2 pathogenic variant probabilities, the benefits 
of breast cancer genetics, and the implications of test re-
sults for treatment compared with those who viewed the 
control version. Second, we aimed to describe patterns of 
genetic testing use among participants in the iCanDecide 
study, who were recruited from community-based surgi-
cal practices in several states.
MATERIALS AND METHODS
Study Design and Patient Recruitment
The current study reports a secondary analysis of data 
collected as part of a randomized controlled trial of a tai-
lored, comprehensive, and interactive decision tool (iCan-
Decide) compared with static online information.16 The 
iCanDecide protocol and primary outcomes analyses have 
been published previously.16,17 A total of 537 newly diag-
nosed patients with early-stage (AJCC stage 0-II) breast 
cancer who were aged 21 to 84 years were enrolled at the 
time of their first visit in 22 surgical practices in 4 states 
(California, Georgia, Michigan, and Tennessee). After re-
ceiving an introduction packet from the surgical practices, 
participants consented online; completed a short survey; 
and were allocated to a study arm using randomization 
stratified by site, age, race, educational level, and timing 
of the surgical consult. Eligible and consenting patients 
within each practice were randomized to the intervention 
(tailored and interactive) or control (static information) ver-
sion of the iCanDecide Web site. The primary outcome 
was a high-quality locoregional treatment decision (de-
fined as an informed decision that was concordant with the 
patient’s values), with knowledge regarding genetic testing 
serving as a secondary outcome. Both were assessed from 
the time of the first follow-up survey, which was mailed 4 
to 5 weeks (496 patients; RR, 92%) after enrollment. A rig-
orous posttest design comparing the intervention with the 
control group with regard to primary and secondary out-
comes was used to increase engagement with the Web site 
and reduce the burden on the respondents associated with 
required baseline questions (iCanDecide intervention Web 
site available at: https://cansort.med.umich.edu/research/
tools-and-resources/).18
Measuring Genetic Testing Knowledge
For the first objective of this analysis, the primary pa-
tient-reported outcomes measured included accurate 
knowledge regarding aspects of genetic testing: 1) the 
probability of carrying a BRCA1 and/or BRCA2 patho-
genic variant (correct/incorrect/did not know); and 2) the 
benefits and purposes of genetic testing after a diagnosis 
of breast cancer.
Knowledge regarding the probability of carrying 
a BRCA1 and/or BRCA2 pathogenic variant
Knowledge regarding the probability of carrying 
a pathogenic variant was measured using an item de-
signed by the study team. Participants were asked: “Out 
of 100 women diagnosed with breast cancer, how many 
have a pathogenic variant in the breast cancer genes 
BRCA1 and/or BRCA2?” Response options included: 
“few (0-10 women),” “some (11-25 women),” “quite a few 
(26-50 women),” “many (51-75 women),” “most (76-100 
woman),” or “don’t know.” Responses were categorized 
as “correct” for participants who selected “few (0-10 
women)” and “incorrect” or “don’t know” for all other 
endorsed response options.
Knowledge regarding the benefits and 
purposes of genetic testing after a diagnosis of 
breast cancer
Knowledge regarding the benefits and purposes of ge-
netic testing was measured using 3 questions developed 
and pilot tested by our clinical team to be consistent with 
the existing knowledge scales for locoregional and sys-
temic treatment also being used in this randomized con-
trolled trial.16,19
Participants were asked if the purposes of genetic 
testing included deciding how to treat, determining the 
probability of a new breast cancer, the prevention of fu-
ture cancers, and informing family members of their risk 
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of breast cancer. Details regarding the survey questions 
are provided in Supporting Information Table 1.
Patterns of Testing in the iCanDecide Sample
At the follow-up survey, participants were asked to pro-
vide information regarding genetic tests that they might 
have undergone as part of the diagnosis or treatment 
of breast cancer or for cancer risk. Participants were 
provided a brief description of the purpose of genetic 
testing. Next, respondents were asked, “Did a doctor 
or other health professional talk with you about hav-
ing a genetic test for breast cancer risk?” (yes/no/do not 
know), “Did you have a counseling session with a ge-
netic counseling expert–that is, an appointment where 
the whole or most of the discussion is about genetic risk 
for breast cancer?” (yes/no/do not know), and “How 
much did you want to have a genetic test to tell you 
the risk of you or your family developing new cancers 
in the future?” (5-point scale from “not at all” to “very 
much”). Participants then were asked, “Have you ever 
had a blood or saliva genetic test for breast cancer risk 
that was ordered by a doctor?” If the participant en-
dorsed that they undergone a doctor-ordered blood or 
saliva genetic test for breast cancer, they were asked 
about their perception regarding why the test was or-
dered, if they had the testing before or after their di-
agnosis, and the result of the genetic testing. However, 
the exact timing of testing or counseling relative to the 
intervention was not known because participants could 
have been tested before or after viewing the Web site. 
Participants who did not have a physician order a mul-
tigene panel test were asked to select why they did not 
undergo genetic testing for breast cancer.
Patient Factors
Patient characteristics were obtained from patient report 
at the time of log in and included age, race, educational 
level, and partnership status. The initial survey also as-
sessed whether the patient had seen her surgeon yet (yes/
no).
Statistical Analysis
To assess genetic testing knowledge, we followed a 
prespecified analytic plan17 to assess whether rates of 
knowledge regarding both knowledge measures (prob-
ability of carrying a BRCA1 and/or BRCA2 pathogenic 
variant and knowledge regarding the benefits and pur-
poses of genetic testing after being diagnosed with 
breast cancer) were higher among the intervention com-
pared with the control participants. Preliminary analy-
ses to explore combining all items into one knowledge 
scale did not indicate that one scale was appropriate. 
Internal consistency (Cronbach alpha, .65) suggested 
that internal reliability was not ideal, even after remov-
ing items with consistently low correlations (correlation 
coefficient [r] <3).
We used chi-square tests and testing was 2-sided, 
with a P value <.05 considered to be statistically signifi-
cant. Participants with missing values regarding the out-
come measures or covariates (<5%) were excluded from 
the analysis. In post hoc analyses, we used logistic regres-
sion to model the association between study condition 
and both dichotomous knowledge outcomes adjusting 
for patient factors that were significant in bivariate anal-
yses as well as study site.
To describe patterns of genetic testing in this clin-
ical sample, we generated descriptive statistics regarding 
TABLE 1. Description of Participant Characteristics
Characteristic
Control Arm (n=270) Intervention Arm (n=267)
p-valueN (%) or mean (SD) N (%) or mean (SD)
Age 57.03 +/- 10.88 (270) 56.52 +/- 10.72 (267) 0.59
Race 0.89
White 212 (79%) 210 (79%)
Black 45 (17%) 42 (16%) .
Other 13 (5%) 15 (6%) .
Education 0.89
High school graduate or less 58 (21%) 57 (21%)
Some college/ college graduate 145 (54%) 148 (55%) .
Some/completed graduate school 67 (25%) 62 (23%) .
Married/Partnered 0.08
No 83 (31%) 64 (24%)
Yes 187 (69%) 203 (76%) .
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patterns of genetic testing and discussion, reasons for the 
provider-ordered genetic test, and participant-reported 
result of the testing.




Study packets were distributed to a total of 1084 pa-
tients, 567 of whom (52.3%) visited the Web site, 
nearly all of whom (537 patients; 94.7%) were eligible, 
created an account, and completed an enrollment sur-
vey  (Fig. 1).16 The response rate to the first follow-up 
survey was 92% (496 patients) in the both intervention 
and control arms (245 patients in the intervention arm 
and 251 in the control arm). The study arms were bal-
anced with regard to demographic factors (Table 1).
Genetic Testing Knowledge
Knowledge about the probability of carrying a 
BRCA1 and/or BRCA2 pathogenic variant
Overall, the rate of knowledge regarding the prob-
ability of having a BRCA1 and/or BRCA2 pathogenic 
variant among women diagnosed with breast cancer 
was low (29.8%) when measured 5 weeks after the first 
surgical visit and after treatment decision making had 
occurred. In bivariate analyses, significantly more pa-
tients in the intervention group compared with the con-
trol group had knowledge regarding their BRCA1 and/
or BRCA2 probability (35.8% vs 24.4%; P = .006). In 
an adjusted multivariable model, patients who viewed 
(267) patients sent 1st folllow 
up survey (4-5 wks)
(4684) New breast cancer 
appointments at participating sites
(1084) study packets given to potential 
eligible patients by site
(567) patients consented on website
(563) patients eligible to participate in 
the study
(540) patients created account on 
website and started baseline survey
(3600) patients not considered for the 
study by sites
(517) patients that did not visit website
(4) patients that did not consent on 
website
(23) patients ineligible to participate
(267) patients randomized to 
intervention and started 
locoregional module
(270) patients randomized to 
control and started locoregional 
module 
(248) patients completed 
locoregional treatment decision 
(270) patients completed 
locoregional treatment decision 
(3) patients did not complete baseline
(19) patients did not complete 
locoregional treatment decision
(0) patients did not complete 
locoregional treatment decision
(537) patients completed baseline 
survey (officially enrolled)
(270) patients sent 1st follow 
up survey (4-5 wks)
(251) patients completed 1st
follow up survey
(included in analytic sample) 
(19) patients did not complete 
1st follow up survey 
(245) patients completed 1st
follow up survey 
(included in analytic sample)
(22) patients did not complete 
1st follow up survey 
Figure 1. Patient participant recruitment diagram for the iCanDecide study.
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the intervention had higher odds than those of the con-
trol group of correctly answering the question regard-
ing the probability of having a BRCA1 and/or BRCA2 
pathogenic variant (odds ratio [OR], 1.79; 95% con-
fidence interval [95% CI], 1.18-2.70) (Fig. 2). Other 
factors found to be significantly associated with odds 
of high knowledge included higher educational levels 
(OR, 2.78; 95% CI, 1.46-5.27). Compared with par-
ticipants who self-reported as white, black patients were 
less likely answer the question regarding the probability 
of having a BRCA1 and/or BRCA2 pathogenic variant 
correctly (OR, 0.29; 95% CI, 0.14-0.60). Older indi-
viduals were less likely than patients aged <49 years to 
answer this question correctly (aged 57-65 years: OR, 
0.44 [95% CI, 0.23-0.73]; and aged >65 years: OR, 
0.33 [95% CI, 0.18-0.60]).
Knowledge regarding the benefits and 
purposes of testing after being diagnosed with 
breast cancer
Patient knowledge regarding the benefits and purposes of 
genetic testing for treatment decision making generally 
was high (percentage correct for each question [range, 
72.49%-89.20%]). In bivariate analyses, the only item 
for which there was a significant difference in the correct 
response noted between the intervention and control sub-
jects was the question regarding whether the purpose of 
undergoing BRCA1 and/or BRCA2 genetic testing after 
a diagnosis of breast cancer is to help a woman know 
whether her family members may be at risk of developing 
breast cancer (95.51% vs 89.21%, respectively; P=.023).
This association held in multivariable logistic re-
gression (OR, 2.75; 95% CI, 1.18-6.43) (Fig. 3). The 
only other factor found to be significantly associated 
with higher odds of knowledge of the benefits and pur-
poses of genetic testing included higher educational level 
(OR, 2.78; 95% CI, 1.22-6.34). There were no differ-
ences regarding the percentage of patients answering the 
other knowledge questions correctly noted by study arm.
Patterns of Testing in the iCanDecide Sample
The majority of survey respondents (71%) stated that 
a health care professional spoke with them about un-
dergoing a genetic test for breast cancer risk. However, 
fewer than one-half of respondents (42%) reported 
having a counseling session with a genetic counseling 
expert. Approximately 56% of respondents endorsed 
that they wanted to undergo genetic testing to learn 
about the risk of future cancers either “quite a bit” or 
“very much.” The percentage of respondents who spoke 
with a health care professional regarding undergoing 
a genetic test and the percentage of respondents who 
endorsed that they wanted to undergo a genetic test 
did not appear to vary by the state in which the sur-
gical practice was located. However, a chi-square test 
of goodness-of-fit determined that the frequencies of 
Figure 2. Results from the logistic regression model regarding the likelihood of a correct response to the knowledge question 
regarding the frequency of women with a pathogenic variant in BRCA1 and/or BRCA2 who already were diagnosed with breast 
cancer. 95% CI indicates 95% confidence interval; CA, California; GA, Georgia; MI, Michigan; TN, Tennessee.
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respondents reporting having a counseling session with 
a genetic counseling expert was higher if the surgical 
practice was located within the state of Georgia com-
pared with the other 3 states (χ2 (9 [496 patients] = 
21.14; P <.04). Among the 196 tested patients, 95.41% 
underwent testing after being diagnosed with breast 
cancer. Approximately 73% said that no pathogenic 
variant was detected, 3.57% stated that they had a 
pathogenic variant in BRCA1 and/or BRCA2 or an-
other gene associated with breast cancer risk, 7.56% 
reported a genetic variant of uncertain significance was 
detected, and 8.67% did not know the results of ge-
netic testing.
Untested participants (254 patients) who were ran-
domized to the intervention group had higher knowl-
edge than control subjects. However, the sample size was 
too small to detect an interaction between testing and 
assigned group in the multivariable logistic regression 
model.
The most commonly selected reasons for getting 
tested were: “My doctor thought I should” (78.57%), 
“I wanted to get more information about my own health” 
(70.41%), and “I wanted to get more information for my 
family member” (68.88%). Among those participants who 
did not undergo testing (278 patients), the most frequently 
endorsed reason for not having genetic testing performed 
was that “my doctor did not recommend it” (59.71%), a 
finding that was similar to previous reports (Table 2).5
DISCUSSION
The results of the current randomized controlled trial, 
which was conducted in a large clinical sample of 
women with a new diagnosis of breast cancer, suggest 
that a decision tool can improve components of knowl-
edge regarding genetic testing. Patterns of testing in 
this sample were similar to those in larger population-
based samples,5 and many women reported that they 
had not received formal genetic counseling. Although 
we did not know the timing of counseling relative to 
study participation, this result confirms findings from 
population-based studies suggesting that there may be 
opportunities for tools to be integrated into the clini-
cal workflow to educate patients regarding the avail-
ability and information that can result from undergoing 
genetic testing.5,20 Prior studies have suggested that 
patients’ recollection and interpretation of complex 
information (eg, pedigree-based hereditary likelihood) 
may differ from what was discussed during a genetic 
counseling session.21‒25 Given that verbal information 
during counseling alone may be inadequate, interactive 
decision tools are one possible way with which to en-
hance and improve patients’ knowledge, and interpreta-
tion of information regarding BRCA1 and/or BRCA2 
genetic testing. Therefore, the potential for online deci-
sion tools to help address patient information needs in 
this complex area is particularly compelling. Although 
not a replacement for professional advice, the findings 
Figure 3. Results from a logistic regression model regarding the likelihood of a correct response to whether undergoing BRCA 
genetic testing after a diagnosis of breast cancer helps a woman know whether her family is at risk of developing breast cancer. 
95% CI indicates 95% confidence interval; CA, California; GA, Georgia; MI, Michigan; TN, Tennessee.
Original Article
4006 Cancer  October 15, 2018
of the current study suggest that online tools can pro-
vide a useful complement.
Although the majority of patients newly diagnosed 
with breast cancer are unlikely to carry a high-risk can-
cer pathogenic variant, the growth of testing options 
and increases in the accessibility of testing underscore 
the importance of ensuring that all individuals have ac-
curate knowledge regarding what the test(s) do, not just 
those who opt to receive genetic testing.26,27 Although 
overall knowledge regarding the probability of carrying 
a BRCA1 and/or BRCA2 pathogenic variant was found 
to be low in this population, the interactive decision tool 
was associated with higher knowledge concerning this 
probability and some of the benefits and purposes of 
 genetics testing after being diagnosed with breast cancer 
when compared with a static Web site. The improvement 
in aspects of knowledge noted after interaction with the 
iCanDecide intervention demonstrates that the inte-
gration of clinical decision support tools into the breast 
cancer treatment decision process can provide additional 
support to patients. The 11.4% increase in genetic testing 
knowledge observed in the current study is promising, 
particularly because genetic testing was not the primary 
focus of the iCanDecide Web site. Despite this positive 
finding, the overall rates of knowledge even in the in-
tervention arm were relatively low (11.4%), suggesting 
an opportunity for further work to improve knowledge 
regarding genetic testing. It is important to note that 
prior work assessing improvements in knowledge con-
cerning locoregional treatment in this population simi-
larly found the need for improvements in knowledge.16 
This work and other reports28‒30 have demonstrated that 
low knowledge exists in patients with breast cancer, even 
after treatment. Persistent low knowledge along with the 
TABLE 2. Participant Patterns of Testing for Breast Cancer
iCanDecide survey question Overall % Endorsed Intervention % Endorsed Control % Endorsed
Did a doctor or other health professional 
talk with you about having a genetic test 
for breast cancer probability ?
335 (70.97) 164 (69.79) 171 (72.15)
Did you have a counseling session with a 
genetic counseling expert – that is, an 
appointment where the whole or most of 
the discussion is about genetic 
probability for breast cancer?
203 (42.12) 99 (41.08) 104 (43.15)
How much did you want to have a genetic 
test to tell you the risk of you or your 
family developing new cancers in the 
future? [quite a bit or very much]
281 (56.65) 142 139
Have you ever had a blood or saliva 
genetic test for breast cancer risk that 
was ordered by a doctor?
Why did you get tested: 
My doctor thought I should 154 (78.57) 79 (79.00) 75 (78.13)
I wanted to get more information about 
my own health
138 (70.41) 72 (72.00) 66 (68.75)
I wanted to get more information for my 
family members
135 (68.88) 69 (69.00) 66 (68.75)
Because of my family history 104 (53.06) 55 (55.00) 49 (51.04)
My family wanted me to be tested 20 (10.20) 11 (11.00) 9 (9.38)
Other 15 (7.65) 5 (5.00) 10 (10.42)
When did you have the test?
Before I was diagnosed 8 (4.08) 4 (4.00) 4 (4.17)
After I was diagnosed 187 (95.41) 96 (96.00) 91 (94.79)
What was the result
I did not have any pathogenic variants in 
the gene tests
144 (73.47) 72 (72.00) 72 (75.00)
I had a pathogenic variant in a gene that 
increases probability of breast cancer 
(BRCA1 or BRCA2)
7 (3.57) 5 (5.00) 2 (2.08)
A gene pathogenic variant was found, 
but not one that has been shown to 
increase risk of BrCa
15 (7.56) 5 (5.00) 10 (10.42)
I don’t know the results 17 (8.67) 10 (10.00) 7 (7.29)
Other 12 (6.12) 8 (8.00) 4 (4.17)
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fact that it remains unclear what is clinically significant 
in this context underscores the need for interventions fo-
cused on enhancing knowledge using novel and engaging 
methods. Tools that offer the ability to link with clini-
cians, or the clinical system, could be useful in providing 
clinicians with additional opportunities to close the loop 
with patients, even after interacting with a decision tool.
Results from the current study indicate that patients 
generally have high knowledge regarding the probability 
of carrying a BRCA1 and/or BRCA2 pathogenic variant 
after being diagnosed with breast cancer, and we did not 
observe an intervention effect on this type of knowledge, 
with the exception of the need to test in family members. 
Although overall knowledge of these items may be high 
in patients with a new breast cancer diagnosis, the po-
tential to influence knowledge regarding the need to test 
family members suggests an area in which tools may be 
particularly useful. However as noted above, the results 
of the current study suggest that there still is considerable 
room to improve the knowledge regarding the probabil-
ity of carrying a BRCA1 and/or BRCA2 pathogenic vari-
ant, particularly in older individuals and patients with 
less education. This also is important given the implica-
tions of having a BRCA1 and/or BRCA2 pathogenic mu-
tation for testing in family members, and cascade testing 
to identify individuals who may be at risk of developing 
breast cancer. Future work should address other factors 
that contribute to lingering knowledge deficits. These 
areas of enhancement include addressing emotional is-
sues (anxiety and worry), which can contribute to the 
ability to truly comprehend cognitively, and providing 
educational materials to the provider that highlight re-
maining knowledge deficits.
The participants in the current study were unique 
in the sense that this was a clinical sample of newly di-
agnosed patients with breast cancer who were recruited 
at the time they were making their surgical treatment 
decision, and most likely reflects what is happening in 
the current clinical context. The majority of participants 
in the current study reported that a health care profes-
sional spoke with them about undergoing a genetic test 
for breast cancer risk. Our patterns of testing are similar 
to those in our prior recent report in a population-based 
sample of patients with breast cancer.6 Nevertheless, sim-
ilar to population-based data, we found that fewer than 
one-half of participants reported having a counseling ses-
sion with a genetic counseling expert. Although sufficient 
pretest counseling could have occurred by other means, 
this finding suggests that the majority of patients did 
not receive optimal pretest discussions regarding genetic 
testing. This also could be the result of an insufficient 
genetic counseling workforce nationwide,14 providing 
further support for tools that address key aspects of ge-
netic testing such as ours.
The findings of the current study are consistent 
with the broader literature concerning the potential pos-
itive impact of interactive online decision aids. Trials 
have demonstrated improvements in the understanding 
of prognosis, treatment options, decisional conflict, and 
satisfaction with the use of decision aids in patients with 
breast cancer as well as other cancers such as colorectal 
cancer and thoracic oncology.31‒34 Furthermore, deci-
sion aids have been shown to weigh the absolute mag-
nitude of benefit against competing risks and ideally 
align choices more closely with the individual patient’s 
personal preferences, particularly within the context of 
genetic testing.13,35
The strengths of the current study included a large, 
diverse sample; detailed information regarding patterns of 
genetic testing; and a high participation rate. Limitations 
included self-report of genetic test results, which may be 
subject to recall bias. Although we achieved good rep-
resentation of patients across subgroups, there remain 
limits to the generalizability of these results to all racial 
and socioeconomic groups, and nonresponse might have 
biased results. Given the importance of genetic testing in 
treatment decision making for patients and family mem-
bers, further work is needed to understand what clinically 
meaningful differences in knowledge regarding genetic 
testing would be from the perspective of clinicians who 
care for patients with breast cancer. Finally, it is import-
ant to note that the current study was conducted prior to 
the widespread adoption of multiplex testing, and there-
fore was focused on individual gene testing. However, we 
suspect that limitations in knowledge will only be exac-
erbated by multiplex testing.
As the scope of and interest in genetic testing 
continues to rise, an already scarce genetic counseling 
workforce is increasingly taxed.3,5,6,14 Offering patients 
decision support tools that educate them regarding 
genetic testing and its relevance to the breast cancer 
treatment decision-making process may be a promis-
ing method for supplementing and supporting genetic 
counselors. Tools can be used to deliver key informa-
tion to patients, tailored to their risk and interest in ge-
netic testing, that can be useful in directing the clinical 
resources for counseling and testing. Moreover, tools 
can be used to inform patients regarding the need for 
family involvement and education concerning genetic 
testing. In addition, tools that can help to calculate 
Original Article
4008 Cancer  October 15, 2018
the probability of an individual carrying a pathogenic 
variant and interest in testing prior to meeting with 
genetic counselors may help to tailor discussions appro-
priately. Nevertheless, the existence of knowledge gaps 
even after tool viewing underscores the importance of 
continued work to engage clinicians in the process of 
educating patients through the integration of tools into 
the clinical and genetic counseling workflow to sup-
port the growing complexity of breast cancer treatment 
decision making.
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